GlassScriptPhysician profile
Kathlyn Andrada
NPI 1962256750
$511.28
in general payments reported to CMS, 2019-2025
12 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $348 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.47 | 2024 | Relistor |
| Scilex Pharmaceuticals INC. | $69.88 | 2024 | |
| Abbvie INC. | $59.73 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $55.08 | 2024 | |
| Lilly USA, LLC | $48.65 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $43.92 | 2024-2025 | Ozempic, Rybelsus |
| Collegium Pharmaceutical, INC. | $36.45 | 2024 | Xtampza |
| Corcept Therapeutics | $22.34 | 2025 | Korlym |
| Cipher Pharmaceuticals US LLC | $18.26 | 2025 | Spinosad, Natroba |
| Pfizer INC. | $17.48 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.44 | 2024 | Rexulti |
| Exact Sciences Corporation | $13.58 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathlyn Andrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.